White House Reaffirms Trump’s Support for Marijuana Reform, Says Administration Continues Exploring National Hemp Framework

The White House has reaffirmed President Trump’s support for marijuana reform, including pointing to his support for the 2024 Florida recreational legalization initiative Amendment 3, while confirming that his administration continues exploring a national regulatory framework for hemp-derived products, including efforts to expand treatment options for veterans and patients.

In comments provided to GreenState and published Tuesday, White House spokeswoman Allison Schuster reiterated the president’s position on marijuana and hemp policy, pointing to his December 2025 executive order and an April 2026 Truth Social post as evidence of his commitment to reform.

Schuster’s comments came in response to questions about whether Trump remains confident that marijuana will be broadly rescheduled under federal law. Although she did not provide a definitive answer or timeline, she emphasized that the president’s position remains consistent with his previous actions and public statements.

“President Trump has made his position on hemp and cannabis abundantly clear, most recently in a December executive order and April TRUTH Social post”, said Schuster. “This position builds on the President’s 2018 Farm Bill, which authorized the production of hemp, and his support for Florida Amendment 3 in 2024.”

The White House also confirmed that the administration continues working toward a potential federal approach to hemp regulation.

“The Administration continues to explore a Gold Science Standard-based framework on hemp to expand treatment options for American veterans and patients,” Schuster said.

The statement comes less than a month before December 11, when significant new federal restrictions on hemp-derived cannabinoid products are scheduled to take effect. Without additional congressional action, the changes could prohibit many products currently sold legally, including certain full-spectrum cannabidiol (CBD) formulations containing THC.

Trump has previously called on Congress to preserve access to appropriate full-spectrum CBD products while establishing safeguards against products that pose serious health risks. His December 18 executive order directed federal officials to work with Congress on revising hemp regulations, including potential limits on THC per serving, per-container restrictions and CBD-to-THC ratios.

In June, The Marijuana Herald reported that the administration formally requested changes to federal hemp regulations in a letter to House Speaker Mike Johnson (R-LA). The White House also supported delaying implementation of the restrictions, which were subsequently postponed until December 11.

In August, a senior Trump adviser told The Marijuana Herald that he supported federal legislation establishing regulations for hemp-derived THC beverages, along with similar protections for edibles and tinctures. The adviser also said Trump still intended to establish a commission examining marijuana descheduling, but that the administration was waiting for the broader rescheduling process to conclude.

On marijuana rescheduling, federal officials have already moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III. However, the broader process that would extend Schedule III classification to marijuana generally, including products sold for recreational use, remains unfinished.

Drug Enforcement Administration (DEA) Administrative Law Judge Derek Julius is expected to issue a recommendation following administrative proceedings that concluded earlier this year. DEA Administrator Terrance Cole will then determine whether to finalize the broader rescheduling proposal.